Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas

Citation
M. Koshiyama et al., Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas, ANTICANC R, 21(2A), 2001, pp. 905-910
Citations number
18
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ANTICANCER RESEARCH
ISSN journal
02507005 → ACNP
Volume
21
Issue
2A
Year of publication
2001
Pages
905 - 910
Database
ISI
SICI code
0250-7005(200103/04)21:2A<905:CBTIAE>2.0.ZU;2-I
Abstract
Background: The purpose of this study was to investigate the correlation be tween topoisomerase II alpha (Topo II alpha) expression and the chemosensit ivity to Topo II-targeting drugs in gynaecological carcinomas. Materials an d Methods: We analysed the expression of Topo II alpha, and then correlated this with the in vitro chemosensitivities of 43 gynaecological tumors usin g immunohistochemistry and a tetrazolium dye (MTT) assay. Results. There wa s a significant correlation between the Topo II alpha index (the number of positive cells per 100 cells: %) and the tumor cell growth inhibition rate in culture (I.R.: %) for doxorubicin and etoposide (r=0.631, p <0.001 and r =0.645, p<0.001, respectively). The I.Rs for doxorubicin and etoposide in e ndometrial carcinomas were lower than those in ovarian carcinomas [38.2<plu s/minus>22.8 vs 54.6 +/- 29.8, 37.3 +/- 19.8 vs 59.3 +/- 30.6](p<0.05, resp ectively). Furthermore, the number of high Topo II-alpha index (over 30%) t umors in the ovarian carcinoma cases was higher than that in the endometria l carcinoma cases (63.1% vs 45.8%, p<0.05). Conclusions. Our data suggest t hat the Topo II-alpha index of a tumor is a reflection of its chemosensitiv ity to Topo II-targeting drugs. The use of this index may enable prediction of a clinical response to chemotherapy using Topo II-targeting drugs in gy naecological malignancies.